Metabolic Syndrome, Prediabetes
Conditions
Keywords
Prediabetes, Metabolic syndrome, Prevention, Lifestyle intervention
Brief summary
The purpose of this study is to examine different methods of delivering the Group Lifestyle Balance (GLB) intervention (1). The GLB is a 12-week lifestyle change program based on the highly successful lifestyle program that was used in the Diabetes Prevention Program (DPP)(2). A DVD of the Group Lifestyle Program has been developed. Conditions called metabolic syndrome and pre-diabetes increase the risk of diabetes and heart disease. Recent research has shown that type 2 diabetes and metabolic syndrome may be prevented or delayed by making lifestyle changes. A primary care practice will enroll participants who will choose either the GLB-DVD intervention or face-to-face group delivery. Approximately 25 patients will be recruited in each group. It is not known if the GLB intervention delivered via DVD is similarly effective to face-to-face group delivery for people with metabolic syndrome or pre-diabetes. It is hoped that this research study will provide information to help answer that question.
Detailed description
The Group Lifestyle Balance program is a 12-session lifestyle intervention with the same goals for weight loss and physical activity as the successful Diabetes Prevention Program (DPP) lifestyle intervention and has been evaluated in several settings. The DPSC collaborated with the US Air Force Center of Excellence for Medical Multimedia to create a DVD of the GLB. The GLB-DVD is a series of taped sessions of a staged group following a script that was developed to closely follow the program. Effectiveness was assessed for the intervention delivered via DVD (GLB-DVD) as well as traditionally in a group setting (GLB-GROUP). For each delivery mode, pre- and 3 month post-intervention measures of weight and the achievement of the program goals were assessed. Secondary outcomes measured included assessment of components of the metabolic syndrome (NCEP ATP III) and HbA1c. The prevention professionals in the practice and the Diabetes Prevention Support Center (DPSC) who provided support for the GLB-DVD and GLB-GROUP participants were health care professionals trained in delivery of the GLB by the DPSC faculty. Group delivery of the GLB was conducted via weekly in person, meetings delivered over 12-15 weeks. For GLB-DVD delivery, an overview of the GLB-DVD and materials was provided at commencement of the intervention. Participants were instructed to view one session/week. At the end of each month the participant was asked to return their DVD via postage-paid mail to the DPSC and the next sequential DVD was mailed to the participant. During GLB-DVD delivery, the DPSC prevention professional contacted the participant weekly via telephone to review weight, physical activity minutes, and questions/concerns regarding the program. Thus, participants in both GLB-GROUP and GLB-DVD were offered a total of 12 health care professional contacts. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity.
Interventions
The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
Sponsors
Study design
Eligibility
Inclusion criteria
* All non-diabetic patients age 18 years and older at the time of enrollment considered to be patients of the practices that are taking part in this project will be eligible for the study upon referral from their physician. * Non-diabetic patients with metabolic syndrome AND/OR pre-diabetes are eligible for the study with referral from their physician based on the following criteria: * Metabolic Syndrome: Patients with BMI greater than or equal to 25 kg/m2, with at least 3 of the following risk factors for metabolic syndrome: * Waist circumference (\>40 inches men, \>35 inches women) * Blood pressure greater than or equal to 130 mmHg (systolic) and/or 85 mmHg (diastolic) OR history of diagnosed hypertension * Low HDL level (\<40mg/dL men, \<50 mg/dL women) * Elevated triglyceride level greater than or equal to 150 mg/dL * Fasting glucose greater than or equal to 100mg/dL and \<126mg/dL * Pre-diabetes: Patients with a BMI greater than or equal to 25 kg/m2 and pre-diabetes (fasting glucose greater than or equal to 100 mg/dL and \<126mg/dL) * All measures should have been taken within six months of enrollment into the study. The physician in each center will be asked to refer eligible patients to the study. It will be the responsibility of the referring physician to determine eligibility and appropriateness of the patient's participation.
Exclusion criteria
* Those patients age less than 18 years old will not be invited to be part of the study. In addition, patients with any of the following conditions are not eligible to take part in the study: * Those with previous diabetes diagnosis * Women who are currently (or within past 6-weeks) pregnant or lactating * Any patient deemed by their physician not to be a candidate * Any patient planning to leave the area before the end of the program * Individuals that are not patients of the participating primary care practices
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Weight | Baseline and 3 months | The primary outcome for this study will be change in weight measured pre and post intervention. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Total Cholesterol | Baseline and 3 months | A secondary outcome for this study will be change in total cholesterol, measured pre and post intervention. |
| Change in HDL Cholesterol | Baseline and 3 months | A secondary outcome for this study will be change in HDL cholesterol, measured pre and post intervention. |
| Change in LDL Cholesterol | Baseline and 3 months | A secondary outcome for this study will be change in LDL cholesterol, measured pre and post intervention. |
| Change in Fasting Glucose | Baseline and 3 months | A secondary outcome for this study will be change in fasting glucose, measured pre and post intervention. |
| Change in Waist Circumference | Baseline and 3 months | A secondary outcome for this study will be change in waist circumference, measured pre and post intervention. |
| Change in Systolic Blood Pressure | Baseline and 3 months | A secondary outcome for this study will be change in systolic blood pressure, measured pre and post intervention. |
| Change in Diastolic Blood Pressure | Baseline and 3 months | A secondary outcome for this study will be change in diastolic blood pressure, measured pre and post intervention. |
| Change in Triglycerides | Baseline and 3 months | A secondary outcome for this study will be change in Triglyceride level, measured pre and post intervention. |
| Change in Hemoglobin A1C | Baseline and 3 months | A secondary outcome for this study will be change in HbA1c, measured pre and post intervention. The hemoglobin HbA1c test provides information regarding how well blood glucose (sugar) has been controlled for the previous 8-12 weeks.. |
Countries
United States
Participant flow
Recruitment details
Patients meeting the criteria for participation were referred by their health care provider, who also provided approval for moderate intensity physical activity. After completing informed consent, participants chose which mode of delivery they preferred, GLB-DVD or GLB-GROUP.
Participants by arm
| Arm | Count |
|---|---|
| GLB Group The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study chose traditional GLB face-to-face group delivery or delivery via DVD. Group members met weekly and completed the program over a 12-15 week period. The face-to-face group meetings were led by a trained lifestyle coach, and participants were encouraged to self-monitor their eating and physical activity behaviors. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity. | 26 |
| GLB DVD The Group Lifestyle Balance program is a direct adaptation of the Diabetes Prevention Program lifestyle intervention. Participants in the study chose traditional GLB face-to-face group delivery or delivery via DVD. Those who took part via DVD received an overview of the GLB program at the first session, as well as the materials needed for the program. They subsequently watched one session of the program each week, and received a telephone call from a trained lifestyle coach each week to review weight, physical activity minutes and questions/concerns regarding the program. Participants in both intervention delivery modes received a GLB workbook, fat and calorie counter, pedometer, and self-monitoring books for tracking food intake and physical activity. | 22 |
| Total | 48 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Job and Health-related | 0 | 3 |
| Overall Study | Other | 2 | 0 |
Baseline characteristics
| Characteristic | GLB Group | GLB DVD | Total |
|---|---|---|---|
| Age, Continuous | 61.0 years STANDARD_DEVIATION 11.9 | 57.3 years STANDARD_DEVIATION 13.6 | 59.1 years STANDARD_DEVIATION 12.8 |
| Region of Enrollment United States | 26 participants | 22 participants | 48 participants |
| Sex: Female, Male Female | 21 Participants | 13 Participants | 34 Participants |
| Sex: Female, Male Male | 5 Participants | 9 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 26 | 0 / 22 |
| serious Total, serious adverse events | 0 / 26 | 0 / 22 |
Outcome results
Change in Weight
The primary outcome for this study will be change in weight measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat using Last Observation Carried Forward (LOCF)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Weight | -13.9 pounds | Standard Deviation 14.3 |
| GLB DVD | Change in Weight | -11.8 pounds | Standard Deviation 11.4 |
Change in Diastolic Blood Pressure
A secondary outcome for this study will be change in diastolic blood pressure, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Diastolic Blood Pressure | -3.6 mmHg | Standard Deviation 7.68 |
| GLB DVD | Change in Diastolic Blood Pressure | -1.43 mmHg | Standard Deviation 6.88 |
Change in Fasting Glucose
A secondary outcome for this study will be change in fasting glucose, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Fasting Glucose | 1.15 mg/dl | Standard Deviation 10.52 |
| GLB DVD | Change in Fasting Glucose | -4.71 mg/dl | Standard Deviation 6.66 |
Change in HDL Cholesterol
A secondary outcome for this study will be change in HDL cholesterol, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in HDL Cholesterol | -2.08 mg/dl | Standard Deviation 5.9 |
| GLB DVD | Change in HDL Cholesterol | -0.72 mg/dl | Standard Deviation 3.71 |
Change in Hemoglobin A1C
A secondary outcome for this study will be change in HbA1c, measured pre and post intervention. The hemoglobin HbA1c test provides information regarding how well blood glucose (sugar) has been controlled for the previous 8-12 weeks..
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Hemoglobin A1C | -0.31 percentage of glycosylated hemoglobin | Standard Deviation 0.25 |
| GLB DVD | Change in Hemoglobin A1C | -0.16 percentage of glycosylated hemoglobin | Standard Deviation 0.23 |
Change in LDL Cholesterol
A secondary outcome for this study will be change in LDL cholesterol, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in LDL Cholesterol | 0.33 mg/dl | Standard Deviation 20.87 |
| GLB DVD | Change in LDL Cholesterol | -2.67 mg/dl | Standard Deviation 14.69 |
Change in Systolic Blood Pressure
A secondary outcome for this study will be change in systolic blood pressure, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Systolic Blood Pressure | -6.55 mmHg | Standard Deviation 11.29 |
| GLB DVD | Change in Systolic Blood Pressure | -4.95 mmHg | Standard Deviation 6.68 |
Change in Total Cholesterol
A secondary outcome for this study will be change in total cholesterol, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Total Cholesterol | -8.29 mg/dl | Standard Deviation 27.09 |
| GLB DVD | Change in Total Cholesterol | -9.94 mg/dl | Standard Deviation 19.08 |
Change in Triglycerides
A secondary outcome for this study will be change in Triglyceride level, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat. Participants with relevant medication changes between baseline and 3 months were excluded.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| GLB Group | Change in Triglycerides | -2.0 mg/dl |
| GLB DVD | Change in Triglycerides | 0 mg/dl |
Change in Waist Circumference
A secondary outcome for this study will be change in waist circumference, measured pre and post intervention.
Time frame: Baseline and 3 months
Population: Intent to treat
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| GLB Group | Change in Waist Circumference | -2.49 inches | Standard Deviation 2.08 |
| GLB DVD | Change in Waist Circumference | -1.87 inches | Standard Deviation 1.98 |